Investor's Business Daily • 31 minutes ago
A single dose of Alder's drug kept migraines down after 24 weeks, but there's still plenty of competition.
Kiplinger • 2 hours ago
Investors don't need to be sold on the beauty of dividends. Dividends have a lot to offer. Companies that boost their dividend payouts regularly typically exhibit qualities associated with superior stock performance over time including strong balance sheets and steady profit and revenue increases.
Zacks • 4 hours ago
Our proven model shows that Amgen (AMGN) is likely to beat earnings because it has the right combination of two key ingredients.
24/7 Wall St. • yesterday
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
Investor's Business Daily Video • 3 days ago
This week, stocks hammered out their fourth straight week of gains as the market develops a more confident tone.
The Wall Street Journal • 4 days ago
Amgen and Allergan on said a late-stage trial of their treatment being developed as a biosimilar to Roche’s breast cancer drug Herceptin met its primary endpoint.
TheStreet.com • 4 days ago
A late-stage trial for Amgen’s (AMGN) drug ABP 980 shows its ‘non-inferiority’ to Roche’s (RHHBY) biosimilar branded product.
|Bid||164.55 x 200|
|Ask||164.63 x 100|
|52wk Range||130.09 - 181.81|
|Day's Range||164.07 - 166.15|
|Avg Vol (3m)||2,805,853|
As of 11:34 AM EDT. NasdaqGS Real Time Price. Market open.